Journal article
The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases
Abstract
High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs. If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition. Excessive regulation produces numerous speed bumps on the road to drug …
Authors
Stewart DJ; Batist G; Kantarjian HM; Bradford J-P; Schiller JH; Kurzrock R
Journal
Clinical Cancer Research, Vol. 21, No. 20, pp. 4561–4568
Publisher
American Association for Cancer Research (AACR)
Publication Date
October 15, 2015
DOI
10.1158/1078-0432.ccr-14-3246
ISSN
1078-0432